Oxlumo®

Understanding Oxlumo® 

Oxlumo® (lumasiran) is an RNA interference (RNAi) therapy designed to reduce the production of oxalate, a substance that contributes to Primary Hyperoxaluria Type 1 (PH1). PH1 is a rare genetic disorder caused by a defect in the AGXT gene, leading to excessive oxalate production that can result in kidney damage and the formation of kidney stones.

How Oxlumo® Works:

• Silences the HAO1 gene in the liver to lower oxalate production
• Reduces oxalate levels, minimizing kidney damage
• Lowers the risk of kidney stone formation, helping to preserve kidney function

FDA Approval:

• Oxlumo® (lumasiran): Approved on November 23, 2020

For more information, please visit the Oxlumo® patient website and speak with your healthcare provider to determine if Oxlumo® is the right treatment option for you.